Legend Biotech is demonstrating successful commercial execution for its CAR-T therapy Carvykti, with revenue accelerating to $387.5M in 2026Q2 and achieving its first positive operating income of $57.7M. However, the company's growth is not yet self-funding, a...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 51.9% YoY in 2026Q2, driving a dramatic shift to a 14.9% operating margin, though gross margin volatility (42.3% to 73.0% over ten quarters) suggests ongoing scaling challenges.
Legend Biotech is focused on developing cutting-edge treatments for hematological malignancies and solid tumors, driving long-term shareholder value.
Regular clinical updates and presentations at key events like ASCO highlight progress in Legend Biotech's pipeline.
Comprehensive SEC filings provide detailed insights into CARVYKTI sales, governance, and risk disclosures, enhancing investor confidence.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | $0.09-25.0% vs $0.12 | $388M+8.9% vs $356M |
Q2 2026 May 12, 2026 | -$0.15-650.0% vs -$0.02 | $305M-0.5% vs $307M |
Q2 2026 Mar 10, 2026 | -$0.08+52.9% vs -$0.17 | $306M-0.5% vs $308M |
Q4 2025 Nov 12, 2025 | -$0.11+15.4% vs -$0.13 | $272M-0.8% vs $274M |
Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster cancer therapy Carvykti.
BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of Directors has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026.
Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.
Updated long-term follow-up data will be presented from CARTITUDE-2 Cohort A in patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy Real-world evidence and post-authorization safety study findings will also be presented BRIDGEWATER, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that data from CARTITUDE-2 and real-world evidence will be presented at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland.
Benchmark LEGN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Legend Biotech Corporation (LEGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $18.45 | $3.41B | -11.53 | 64.04% | -28.85% | -29.06% | — | |
| $2.43 | $283.24M | -2.11 | -51.24% | -1941.09% | -65.08% | — | |
| $55.76 | $5.38B | -8.62 | -89.97% | -3368.72% | -24.39% | — | |
| $24.37 | $2.51B | -30.09 | 120.01% | -54.75% | -7.7% | — | |
| $12.33 | $1.38B | -3.24 | 16.92% | -672.16% | -57.79% | — | |
| $2.69 | $412.81M | -1.49 | 25.39% | -157.32% | -196.63% | — |
Legend Biotech Corporation (LEGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when LEGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Legend Biotech Corporation (LEGN) stock FAQ — growth, dividends, profitability & financials explained
Legend Biotech Corporation (LEGN) reported $1.27B in revenue for fiscal year 2025. This represents a 5288% increase from $23.6M in 2017.
Legend Biotech Corporation (LEGN) grew revenue by 64.0% over the past year. This is strong growth.
Legend Biotech Corporation (LEGN) reported a net loss of $91.6M for fiscal year 2025.
Legend Biotech Corporation (LEGN) has a return on equity (ROE) of -29.1%. Negative ROE indicates the company is unprofitable.
Legend Biotech Corporation (LEGN) had negative free cash flow of $255.6M in fiscal year 2025, likely due to heavy capital investments.
